☆ 4.6 Article

Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Global, regional and national burden of primary liver cancer by subtype

Harriet Rumgay et al.

Summary: This study provides worldwide, regional, and national estimates of the incidence of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). The results show that HCC contributes the largest burden of liver cancer globally, with the highest rates in Eastern Asia, Northern Africa, and Southeastern Asia. iCCA rates are highest in Southeastern Asia, Eastern Asia, Northern Europe, the Caribbean and Central America, and Oceania.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

Philip Johnson et al.

Summary: This review discusses biomarkers for hepatocellular carcinoma (HCC) that can improve early diagnosis, therapy monitoring, and prediction of therapy response. The sensitivity of surveillance methods for HCC, such as abdominal ultrasonography and alpha-fetoprotein (AFP) analysis, is limited. Two approaches, using AFP within statistical models and circulating nucleic acid biomarkers, show promise in overcoming this limitation.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma

Katherine A. McGlynn et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a major global health concern. While HBV and HCV remain important risk factors for HCC, efforts in vaccination and treatment are showing promise. However, the increasing prevalence of metabolic risk factors like obesity and diabetes, as well as other factors like excessive alcohol consumption, present ongoing challenges in the prevention of liver cancer.

HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Surgical Treatments of Hepatobiliary Cancers

Ganesh Gunasekaran et al.

Summary: Hepatobiliary cancers, including HCC and biliary tract cancers, have significant morbidity and mortality rates. Treatment options vary based on disease stage, with surgical resection offering potential cure for early-stage disease, while ablation and liver transplantation can be considered for inoperable cases. Multi-disciplinary evaluation is essential for optimal management of these cancers.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Impact of COVID-19 on global HCV elimination efforts

Sarah Blach et al.

Summary: The study focused on the impact of COVID-19 on hepatitis elimination programs, finding that a 1-year delay in diagnosis and treatment could lead to an additional 44,800 liver cancers and 72,300 HCV-related deaths globally by 2030. It emphasizes the importance of prioritizing hepatitis programs as soon as it becomes safe to do so.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology

Ashish Manne et al.

Summary: Recent advancements in precision medicine have made it possible to identify new molecular markers for BTCs, including epigenetic changes and non-DNA markers, providing hope for improved diagnosis and treatment outcomes.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Comparison of liver cancer incidence and survival by subtypes across seven high-income countries

Mark J. Rutherford et al.

Summary: International comparison of liver cancer survival faces challenges due to differences in morphological verification standards and coding practices. This article presents comparisons of liver cancer survival across ICBP jurisdictions and highlights the poor survival rates in all countries. Australia has the highest survival rates, especially for morphologically verified tumors.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Review Oncology

Next-Generation Biomarkers for Cholangiocarcinoma

Pedro M. Rodrigues et al.

Summary: The early and non-invasive diagnosis of cholangiocarcinoma (CCA) remains a challenge, contributing to increased mortality rates globally. Efforts to identify novel biomarkers for CCA diagnosis and prognosis prediction are ongoing, with the hope of improving patient outcomes in the future. High-throughput omics-based approaches hold promise for identifying circulating biomarkers that may aid in early detection and treatment stratification in large-scale validation studies.

CANCERS (2021)

Add to Collection

Review Oncology

Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges

Alessandro Rizzo et al.

Summary: Ampullary carcinomas are rare tumors with limited data on optimal treatment strategies, posing challenges for physicians. This review provides an overview of the biological and histological characteristics of AC, as well as available data guiding current and future therapeutic strategies.

CURRENT ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Klatskin Tumor in the Light of ICD-O-3: A Population-Based Clinical Outcome Study Involving 1,144 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (2001-2012)

Jaffar Khan et al.

Summary: The study investigated demographic, clinical, and pathological factors affecting the prognosis and survival of Klatskin tumors (KT) in 1,144 patients from the SEER database. Findings showed that KT primarily occurred in older Caucasian men, and surgical resection did not provide significant survival advantage. Proper histological grading was found to be crucial for predicting prognosis.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents

Fasiha Kanwal et al.

HEPATOLOGY (2020)

Add to Collection

Review Gastroenterology & Hepatology

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis

Oliver Clements et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up

Christian S. Alvarez et al.

HEPATOLOGY (2020)

Add to Collection

Article Oncology

International trends in hepatocellular carcinoma incidence, 1978-2012

Jessica L. Petrick et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Article Surgery

Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017

Andrew J. Weaver et al.

JOURNAL OF SURGICAL RESEARCH (2020)

Add to Collection

Article Gastroenterology & Hepatology

EASL recommendations on treatment of hepatitis C: Final update of the series

Jean-Michel Pawlotsky et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

David Bomze et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Gastroenterology & Hepatology

From NASH to HCC: current concepts and future challenges

Quentin M. Anstee et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Projections of primary liver cancer to 2030 in 30 countries worldwide

Patricia C. Valery et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach et al.

HEPATOLOGY (2018)

Add to Collection

Review Gastroenterology & Hepatology

Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue

Changqing Zhao et al.

LIVER INTERNATIONAL (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Review Medicine, General & Internal

Hepatocellular carcinoma

Alejandro Forner et al.

LANCET (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Multidisciplinary Sciences

Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030

Benedikt Schaefer et al.

PLOS ONE (2018)

Add to Collection

Review Gastroenterology & Hepatology

Review article: systemic treatment of hepatocellular carcinoma

Matthias Pinter et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Article Gastroenterology & Hepatology

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease

Fasiha Kanwal et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Oncology

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study

Ian Chau et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

Reem Waziry et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Gastroenterology & Hepatology

Global trends and predictions in hepatocellular carcinoma mortality

Paola Bertuccio et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

Add to Collection

Article Oncology

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. W. Valle et al.

ANNALS OF ONCOLOGY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Jesus M. Banales et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)

Add to Collection

Article Oncology

Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise

Supriya K. Saha et al.

ONCOLOGIST (2016)

Add to Collection

Article Gastroenterology & Hepatology

Epidemiological Trends of Hepatocellular Carcinoma in Austria

Matthias Pinter et al.

DIGESTIVE DISEASES (2014)

Add to Collection

Article Gastroenterology & Hepatology

Incidence and mortality trends for biliary tract cancers in Austria

Matthias Pinter et al.

LIVER INTERNATIONAL (2014)

Add to Collection

Article Medicine, General & Internal

Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis

Amit G. Singal et al.

PLOS MEDICINE (2014)

Add to Collection

Article Oncology

Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

John D. Hainsworth et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Gastroenterology & Hepatology

Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?

Shahid A. Khan et al.

JOURNAL OF HEPATOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program?

Florian Hucke et al.

WIENER KLINISCHE WOCHENSCHRIFT (2011)

Add to Collection

Article Medicine, General & Internal

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.

Juan Valle et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Oncology

Gallstones and the risk of biliary tract cancer: a population-based study in China

A. W. Hsing et al.

BRITISH JOURNAL OF CANCER (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.